Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Piriformis Syndrome Market

ID: MRFR/HC/55049-HCR
200 Pages
Rahul Gotadki
April 2026

UK Piriformis Syndrome Market Research Report By Cause (Trauma, Spasms, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Piriformis Syndrome Market Infographic
Purchase Options

UK Piriformis Syndrome Market Summary

As per Market Research Future analysis, the UK piriformis syndrome market Size was estimated at 0.01 USD Million in 2024. The UK piriformis syndrome market is projected to grow from 0.01 USD Million in 2025 to 0.02 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.6% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The UK piriformis syndrome market is experiencing a notable shift towards enhanced treatment modalities and increased awareness.

  • Rising awareness and education about piriformis syndrome are driving patient engagement and treatment-seeking behavior.
  • Advancements in treatment options, particularly non-invasive therapies, are reshaping patient management strategies.
  • The integration of multidisciplinary approaches is becoming more prevalent, enhancing overall treatment efficacy.
  • The increasing incidence of piriformis syndrome and growing demand for non-invasive treatment options are key market drivers.

Market Size & Forecast

2024 Market Size 0.01 (USD Million)
2035 Market Size 0.02 (USD Million)
CAGR (2025 - 2035) 6.67%

Major Players

Medtronic (US), Johnson & Johnson (US), Stryker (US), Boston Scientific (US), Abbott Laboratories (US), Baxter International (US), Smith & Nephew (GB), NuVasive (US), Orthofix Medical (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

UK Piriformis Syndrome Market Trends

The piriformis syndrome market is currently experiencing notable developments, driven by an increasing awareness of the condition and its impact on individuals' quality of life. Piriformis syndrome, characterized by pain in the buttocks and potential sciatica, has garnered attention from healthcare professionals and patients alike. This heightened awareness is leading to a rise in demand for effective treatment options, including physical therapy, medications, and alternative therapies. As a result, healthcare providers are adapting their approaches to address the needs of those affected, which may contribute to a more comprehensive understanding of the syndrome and its management. Moreover, the piriformis syndrome market is influenced by advancements in diagnostic techniques and treatment modalities. Enhanced imaging technologies allow for more accurate diagnoses, which can lead to timely and appropriate interventions. Additionally, the integration of multidisciplinary approaches in treatment plans is becoming more prevalent, as practitioners recognize the importance of addressing both physical and psychological aspects of the condition. This trend suggests a shift towards a more holistic view of patient care, potentially improving outcomes for individuals suffering from piriformis syndrome. As the market evolves, ongoing research and collaboration among healthcare professionals will likely play a crucial role in shaping future developments.

Rising Awareness and Education

There is a growing emphasis on educating both healthcare providers and patients about piriformis syndrome. This trend is likely to enhance understanding of the condition, leading to earlier diagnoses and more effective treatment strategies.

Advancements in Treatment Options

Innovations in treatment modalities, including physical therapy techniques and alternative therapies, are emerging within the piriformis syndrome market. These advancements may provide patients with more effective and personalized care.

Integration of Multidisciplinary Approaches

The trend towards multidisciplinary care is becoming more pronounced, as healthcare professionals collaborate to address the various aspects of piriformis syndrome. This approach may improve patient outcomes by considering both physical and psychological factors.

UK Piriformis Syndrome Market Drivers

Rising Healthcare Expenditure

Rising healthcare expenditure in the UK is a significant driver for the piriformis syndrome market. As the government allocates more funds to healthcare services, there is an increased capacity for the diagnosis and treatment of various conditions, including piriformis syndrome. The UK healthcare budget has seen a steady increase, with a focus on improving patient outcomes and access to care. This financial commitment is likely to enhance the availability of treatment options and support research into new therapies. Consequently, the piriformis syndrome market may experience growth as healthcare providers are better equipped to address the needs of patients suffering from this condition.

Increased Focus on Pain Management

The increased focus on pain management within the UK healthcare system is a critical driver for the piriformis syndrome market. Chronic pain conditions, including piriformis syndrome, are receiving heightened attention as they significantly impact quality of life. The National Health Service (NHS) has been implementing strategies to improve pain management services, which may include multidisciplinary approaches to treatment. This focus is likely to lead to an increase in referrals for specialized care, thereby expanding the market for piriformis syndrome treatments. As awareness of effective pain management strategies grows, the demand for targeted therapies is expected to rise.

Increasing Incidence of Piriformis Syndrome

The rising incidence of piriformis syndrome in the UK is a notable driver for the piriformis syndrome market. Factors such as sedentary lifestyles, increased participation in sports, and prolonged sitting contribute to the growing prevalence of this condition. Recent studies indicate that approximately 6-8% of individuals with sciatica may actually have piriformis syndrome, suggesting a significant underdiagnosis. This growing recognition of the condition is likely to drive demand for diagnostic tools and treatment options within the market. As healthcare providers become more aware of the syndrome, the need for effective management strategies will likely increase, thereby expanding the market's potential.

Technological Advancements in Diagnostic Tools

Technological advancements in diagnostic tools are transforming the landscape of the piriformis syndrome market. Innovations such as MRI and ultrasound imaging have enhanced the ability to accurately diagnose piriformis syndrome, which is often misdiagnosed. The introduction of these advanced imaging techniques has led to a more precise identification of the condition, allowing for timely and appropriate treatment. As the UK healthcare system increasingly adopts these technologies, the market for piriformis syndrome is expected to grow. The integration of artificial intelligence in imaging analysis may further streamline diagnosis, potentially increasing patient throughput and improving outcomes.

Growing Demand for Non-Invasive Treatment Options

There is a growing demand for non-invasive treatment options in the piriformis syndrome market, reflecting a broader trend in healthcare towards conservative management. Patients are increasingly seeking alternatives to surgical interventions, which can be costly and carry significant risks. Non-invasive treatments such as physical therapy, chiropractic care, and corticosteroid injections are gaining popularity. According to recent data, non-invasive therapies can lead to symptom relief in up to 80% of patients with piriformis syndrome. This shift in patient preference is likely to drive market growth as healthcare providers adapt to meet the demand for safer, less invasive treatment modalities.

Market Segment Insights

By Cause: Spasms (Largest) vs. Overuse injury (Fastest-Growing)

In the UK piriformis syndrome market, the causes of the condition are diverse, with trauma, spasms, overuse injuries, and other factors contributing to the landscape. Among these, spasms hold the largest market share, demonstrating a significant prevalence in patients suffering from piriformis syndrome, followed closely by trauma-related incidents. Overuse injuries, while still notable, are emerging as a key concern that is gaining traction among healthcare providers and patients alike. Growth trends indicate that the emphasis on physical therapy and rehabilitation for overuse injuries is driving their rapid expansion. Increased awareness of activity-related injuries and a shift towards preventative healthcare measures are key factors contributing to this growth. Meanwhile, spasms continue to dominate due to their established association with chronic pain, necessitating ongoing treatment and management strategies in patient care.

Spasms (Dominant) vs. Overuse injury (Emerging)

Spasms are currently the dominant cause of piriformis syndrome within this market segment, often resulting from muscular tension in the hip area, leading to pain and discomfort that significantly affects daily activities. This condition is frequently highlighted in clinical practices as a primary focus for treatment, as it directly links to patient experiences of chronic pain. Conversely, overuse injuries are emerging, capturing attention due to their increasing incidence, particularly among athletes and individuals engaging in repetitive movements. As awareness grows, so does the demand for effective management strategies. Both segments exhibit unique characteristics, but current trends in fitness and rehabilitation emphasize the importance of addressing overuse injuries to mitigate long-term complications, making them a focal point for future market development.

By Diagnostic Test: MRI (Largest) vs. EMG (Fastest-Growing)

In the diagnostic test segment of the UK piriformis syndrome market, Magnetic Resonance Imaging (MRI) holds the largest market share, being widely favored for its ability to provide detailed images of soft tissues. Following MRI, other diagnostic tests such as X-rays and Neurophysiologic Testing have notable shares, but MRI remains the go-to choice among healthcare professionals for diagnosing piriformis syndrome due to its non-invasive nature and high resolution. Conversely, Electromyography (EMG) is emerging as the fastest-growing segment, driven by increasing awareness of neuromuscular disorders and advancements in technology that enhance its accuracy and efficiency. The rise of telehealth and online consultations has also contributed to the increased utilization of EMG, as it becomes more accessible and convenient for practitioners. As the market evolves, these dynamics highlight the varying roles that each diagnostic test plays in managing and diagnosing piriformis syndrome effectively.

MRI (Dominant) vs. EMG (Emerging)

Magnetic Resonance Imaging (MRI) is considered the dominant diagnostic tool in the UK piriformis syndrome market, offering high-resolution images that are crucial for identifying any anatomical abnormalities associated with the condition. Its non-invasive nature allows for comprehensive evaluation without the need for surgical procedures, making it the preferred choice among clinicians. Meanwhile, Electromyography (EMG) is rapidly emerging as a vital diagnostic method that assesses the electrical activity of muscles and nerves. This test is particularly valuable in understanding neuromuscular interactions and evaluating the extent of nerve damage or impingement related to piriformis syndrome. Both tests play complementary roles, with MRI identifying structural issues and EMG providing functional insights.

By Treatment: Medication (Largest) vs. Physical Therapy (Fastest-Growing)

In the UK piriformis syndrome market, the treatment segment showcases a diverse array of approaches, with medication holding the largest share. This includes over-the-counter pain relievers and prescription medications, which are crucial for managing symptoms effectively. Physical therapy is gaining traction, recognized for its pivotal role in rehabilitation and recovery, contributing to a significant portion of the market as consumers seek non-invasive methods to alleviate their pain. Emerging trends indicate a shift towards holistic and integrative approaches, with physical therapy witnessing the fastest growth. Patients increasingly prefer treatments that combine physical rehabilitation with complementary options such as acupuncture and osteopathic manipulative treatment (OMT), reflecting a broader acceptance of diverse therapeutic strategies. The uk piriformis syndrome market is thus adapting to meet these evolving consumer preferences, driven by both awareness and demand for less invasive treatment alternatives.

Medication: Medication (Dominant) vs. Physical Therapy (Emerging)

Medication remains the dominant treatment strategy within the UK piriformis syndrome market, primarily due to its accessibility and efficacy in delivering quick symptom relief. Over-the-counter options like NSAIDs and acetaminophen are commonly chosen first-line therapies. Conversely, Physical Therapy is emerging as a formidable alternative, emphasizing rehabilitation through targeted exercises and manual therapy techniques. Patients favor this non-invasive treatment method, which aligns with a growing trend toward preventive care and personalized therapeutic regimes. Both segments complement each other, as medication often acts as a support system while physical therapy aims to address the underlying causes of pain. This dynamic positions both medication and physical therapy as integral components of effective treatment plans.

By Distribution Channel: E-Commerce (Largest) vs. Retail Pharmacies (Fastest-Growing)

The distribution of the UK piriformis syndrome market across various channels reveals that E-Commerce holds the largest share, driven by the increasing consumer preference for online shopping. Retail pharmacies form the next significant segment, appealing to consumers seeking instant access to pain relief products. The 'Others' category, though important, contributes less substantially to overall market share, indicating a more niche presence within the healthcare landscape. Growth trends indicate a robust rise in E-Commerce, propelled by convenience and a wider product range. In contrast, retail pharmacies are witnessing increased foot traffic as patients prioritize immediate solutions for piriformis syndrome. The overall trend reflects a balanced shift towards digital platforms while maintaining traditional retail, carving out distinct growth paths for each segment.

E-Commerce (Dominant) vs. Retail Pharmacies (Emerging)

E-Commerce has established itself as the dominant distribution channel in the UK piriformis syndrome market, appealing significantly to tech-savvy consumers who appreciate the convenience of online shopping. Its ability to offer a vast array of products and competitive pricing contributes to its strong market position. On the other hand, retail pharmacies are emerging as vital players in this space, focusing on personalized customer service and immediate availability of treatments. As they adapt to the changing healthcare landscape by enhancing in-store experiences and embracing digital innovation, retail pharmacies are carving a substantial niche, catering to those who prefer direct interaction and instant solutions for their healthcare needs.

By End-User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the UK piriformis syndrome market, the distribution of market share among end-users shows that Hospitals & Clinics hold the largest segment. This dominance is primarily driven by the comprehensive range of services they provide, making them the first choice for patients seeking treatment. On the other hand, Diagnostic Centers are witnessing rapid growth, capturing an increasing share due to their specialized diagnostic capabilities and advanced imaging technologies. The growth trends within this segment are being propelled by the rising prevalence of piriformis syndrome and a greater awareness of the condition among healthcare providers and patients alike. The demand for advanced diagnostic tools and faster access to treatment options is leading to increased investments in these centers. This growth is further supported by the expanding network of outpatient services and telehealth solutions, making care more accessible and efficient.

Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals & Clinics serve as the dominant segment within the UK piriformis syndrome market, offering a full spectrum of diagnostic and therapeutic services under one roof. They are equipped with the latest technologies and staffed by multidisciplinary teams, allowing for comprehensive patient management from diagnosis to treatment and rehabilitation. Their established reputation and integrated care models make them the preferred choice for many patients. Conversely, Diagnostic Centers are emerging rapidly due to their focused service offerings and specialization in diagnostic procedures. These centers are increasingly recognized for their efficiency in providing assessments and imaging services. Their ability to supplement hospital care with swift and accurate diagnosis positions them as vital players, attracting a growing patient population seeking quick and reliable evaluations.

Get more detailed insights about UK Piriformis Syndrome Market

Key Players and Competitive Insights

The competitive dynamics within the piriformis syndrome market are characterized by a blend of innovation, strategic partnerships, and regional expansion. Key players such as Medtronic (US), Johnson & Johnson (US), and Smith & Nephew (GB) are actively shaping the landscape through their operational focuses. Medtronic (US) emphasizes technological advancements in pain management solutions, while Johnson & Johnson (US) is leveraging its extensive portfolio to enhance patient outcomes through innovative surgical techniques. Smith & Nephew (GB) appears to be concentrating on expanding its product offerings in minimally invasive procedures, which aligns with the growing demand for less invasive treatment options. Collectively, these strategies foster a competitive environment that is increasingly driven by technological innovation and patient-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. This fragmentation allows for diverse approaches to treatment and innovation, although the influence of major players remains significant. The collective actions of these key companies contribute to a dynamic market where adaptability and responsiveness to patient needs are paramount.

In October Medtronic (US) announced the launch of a new line of neuromodulation devices specifically designed for chronic pain management, including piriformis syndrome. This strategic move is likely to enhance Medtronic's market position by addressing a critical need for effective pain relief solutions, thereby potentially increasing its market share in the UK. The introduction of these devices reflects a commitment to innovation and aligns with the growing trend towards personalized medicine.

In September Johnson & Johnson (US) entered into a partnership with a leading UK-based healthcare provider to develop integrated care pathways for patients suffering from piriformis syndrome. This collaboration is expected to streamline treatment processes and improve patient outcomes, indicating a strategic focus on enhancing service delivery through partnerships. Such alliances may also facilitate access to a broader patient base, thereby strengthening Johnson & Johnson's competitive edge in the market.

In August Smith & Nephew (GB) acquired a small medical device company specializing in advanced imaging technologies for surgical procedures. This acquisition is anticipated to bolster Smith & Nephew's capabilities in providing comprehensive solutions for piriformis syndrome treatment, particularly in surgical settings. By integrating advanced imaging into its offerings, the company may enhance surgical precision and patient safety, which are critical factors in the competitive landscape.

As of November current trends in the piriformis syndrome market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are playing a pivotal role in shaping the landscape, as companies seek to leverage complementary strengths to enhance their offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of developing robust, patient-centered solutions that not only address immediate needs but also anticipate future healthcare challenges.

Key Companies in the UK Piriformis Syndrome Market include

Industry Developments

The UK Piriformis Syndrome Market has experienced notable developments in recent months, with a growing emphasis on physiotherapy and advanced treatment options. The rise in awareness regarding the condition has led to an increase in services offered by organizations like The London Clinic, Nuffield Health, and HCA Healthcare, focusing on tailored physiotherapy treatments. In October 2023, Bupa announced an expanded collaboration with Bristol Physiotherapy aimed at enhancing patient access to specialized care for musculoskeletal disorders, including piriformis syndrome. 

Additionally, a merger occurred in September 2023 between MediKidz and Aspire Physiotherapy, strengthening their combined outreach and expertise in pain management. The advancement in technology and treatment protocols has resulted in substantial growth in market valuation, positioning firms like Pure Sports Medicine and Ramsay Santé favorably within the industry. 

Over the past two years, the UK market has seen a significant investment in Research and Development, leading to innovative therapies and improved patient outcomes. Collaboration among physiotherapy clinics, especially in major cities, has enhanced service delivery, benefiting patients with piriformis syndrome. Overall, the market trend is leaning towards integrated healthcare solutions focusing on individualized care.

Future Outlook

UK Piriformis Syndrome Market Future Outlook

The Piriformis Syndrome Market is projected to grow at a 6.67% CAGR from 2025 to 2035, driven by increasing awareness, innovative treatment options, and rising healthcare expenditure.

New opportunities lie in:

  • Development of telehealth platforms for remote consultations and follow-ups.
  • Investment in targeted physical therapy programs tailored for piriformis syndrome.
  • Creation of specialized ergonomic products to alleviate symptoms in workplaces.

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient engagement.

Market Segmentation

UK Piriformis Syndrome Market Cause Outlook

  • Trauma
  • Spasms
  • Overuse injury
  • Others

UK Piriformis Syndrome Market End-User Outlook

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

UK Piriformis Syndrome Market Treatment Outlook

  • Medication
  • Physical Therapy
  • Acupuncture
  • Prolotherapy
  • Osteopathic Manipulative Treatment (OMT)
  • Surgery
  • Others

UK Piriformis Syndrome Market Diagnostic Test Outlook

  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • X-rays
  • Neurophysiologic Testing
  • Electromyography (EMG)
  • Beatty Test
  • FAIR (Flexion, adduction, and Internal Rotation) Test
  • Others

UK Piriformis Syndrome Market Distribution Channel Outlook

  • E-Commerce
  • Retail Pharmacies
  • Others

Report Scope

MARKET SIZE 2024 0.01(USD Million)
MARKET SIZE 2025 0.01(USD Million)
MARKET SIZE 2035 0.02(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.67% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Medtronic (US), Johnson & Johnson (US), Stryker (US), Boston Scientific (US), Abbott Laboratories (US), Baxter International (US), Smith & Nephew (GB), NuVasive (US), Orthofix Medical (US)
Segments Covered Cause, Diagnostic Test, Treatment, Distribution Channel, End-User
Key Market Opportunities Emerging therapies and digital health solutions enhance management of piriformis syndrome symptoms.
Key Market Dynamics Rising demand for innovative therapies drives competition in the piriformis syndrome treatment landscape.
Countries Covered UK
Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Leave a Comment

FAQs

What is the projected market valuation for the UK piriformis syndrome market in 2035?

The projected market valuation for the UK piriformis syndrome market in 2035 is $0.02 Million.

What was the market valuation for the UK piriformis syndrome market in 2024?

The market valuation for the UK piriformis syndrome market in 2024 was $0.01 Million.

What is the expected CAGR for the UK piriformis syndrome market from 2025 to 2035?

The expected CAGR for the UK piriformis syndrome market during the forecast period 2025 - 2035 is 6.67%.

Which companies are key players in the UK piriformis syndrome market?

Key players in the UK piriformis syndrome market include Medtronic, Johnson & Johnson, Stryker, and Boston Scientific.

What are the main causes of piriformis syndrome as per market segmentation?

The main causes of piriformis syndrome include trauma, spasms, and overuse injury, with respective valuations of $0.0025 Million, $0.0035 Million, and $0.0025 Million.

What diagnostic tests are utilized for piriformis syndrome?

Diagnostic tests for piriformis syndrome include MRI, CT, and X-rays, with valuations of $0.0035 Million, $0.0025 Million, and $0.0015 Million respectively.

What treatment options are available for piriformis syndrome?

Treatment options for piriformis syndrome encompass medication, physical therapy, and acupuncture, with valuations of $0.0025 Million, $0.003 Million, and $0.0015 Million respectively.

How is the UK piriformis syndrome market distributed across different channels?

The UK piriformis syndrome market is distributed through channels such as e-commerce and retail pharmacies, with valuations of $0.0035 Million and $0.005 Million respectively.

What are the end-user segments in the UK piriformis syndrome market?

End-user segments in the UK piriformis syndrome market include hospitals & clinics and diagnostic centers, with valuations of $0.004 Million and $0.003 Million respectively.

What does the future hold for the UK piriformis syndrome market?

The future of the UK piriformis syndrome market appears promising, with a projected growth to $0.02 Million by 2035.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions
%>